Discontinued — last reported Q1 '24
West Pharmaceutical Services Smart Dose — Deferred income, current remained flat by 0.0% to $900.00K in Q1 2024 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $900.00K to $900.00K. Over 2 years (FY 2021 to FY 2023), Smart Dose — Deferred income, current shows relatively stable performance with a 0.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher levels indicate a robust near-term revenue pipeline, whereas declining levels may signal a reduction in upcoming project milestones or service deliveries.
Represents the portion of deferred income related to the Smart Dose platform that is expected to be recognized as revenu...
Comparable to current contract liabilities or short-term deferred revenue reported by peers in the life sciences and medical technology sectors.
wst_segment_smart_dose_deferred_income_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $900.00K | $900.00K | $900.00K | $900.00K | $900.00K | $900.00K | $900.00K | $900.00K | $900.00K | $900.00K | $900.00K | $900.00K |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |